You are here: Industry Insights > Can-Fite

News List

Can-Fite BioPharma enrols first patient to study Covid-19 drug pharmaceutical-technology
March 09, 2021
Can-Fite BioPharma has enrolled the first patient in a Phase II study of its drug, Piclidenoson, to treat hospitalised patients with moderate to severe Covid-19.
Can-Fite announces pre-IND submission to US FDA for Piclidenoson in treatment of Covid-19 infected p pharmaceutical-business-review
May 21, 2020
Can-Fite BioPharma announced it has filed a pre-Investigational New Drug (IND) meeting request with the U.S. Food and Drug Administration (FDA) for its drug candidate Piclidenoson in the treatment of COVID-19 patients with moderate-to-severe symptoms.
Can-Fite says liver cancer trial is delayed—but it could be good news fiercebiotech
June 25, 2018
Israeli microcap Can-Fite BioPharma won’t get a readout from its midstage trial of liver cancer candidate namodenoson as soon as it hoped, but said the data so far are looking good.
Can-Fite 12 Months' Activities & Milestones for 2018 biospace
January 12, 2018
Can-Fite BioPharmaceuticals today announced its 2018 milestone, including activities involving rheumatoid arthritis / psoriasis drug Piclidenoson and liver disease drug Namodenoson.